Vaxart (NASDAQ:VXRT) Shares Up 6.6%

Vaxart, Inc. (NASDAQ:VXRT)’s share price shot up 6.6% during trading on Wednesday . The company traded as high as $7.97 and last traded at $7.89. 65,736 shares were traded during mid-day trading, a decline of 100% from the average session volume of 16,927,213 shares. The stock had previously closed at $7.40.

A number of research firms have recently commented on VXRT. Zacks Investment Research upgraded Vaxart from a “sell” rating to a “hold” rating in a research report on Wednesday, May 5th. B. Riley restated a “buy” rating and issued a $13.00 price objective (down from $16.00) on shares of Vaxart in a research report on Thursday, March 4th.

The stock has a market cap of $876.66 million, a PE ratio of -15.26 and a beta of 0.27. The company has a 50-day moving average of $6.65.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings results on Sunday, May 2nd. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.04). Vaxart had a negative return on equity of 39.81% and a negative net margin of 2,844.24%. The firm had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.62 million. The company’s revenue for the quarter was down 82.8% compared to the same quarter last year. Equities analysts anticipate that Vaxart, Inc. will post -0.75 earnings per share for the current fiscal year.

In related news, Director Wouter Latour sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, May 7th. The stock was sold at an average price of $7.13, for a total transaction of $713,000.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at $713,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 36.70% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of VXRT. BNP Paribas Arbitrage SA boosted its stake in Vaxart by 32.4% during the first quarter. BNP Paribas Arbitrage SA now owns 7,383 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,805 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Vaxart by 7.3% during the fourth quarter. The Manufacturers Life Insurance Company now owns 32,404 shares of the biotechnology company’s stock worth $185,000 after buying an additional 2,217 shares during the last quarter. Swiss National Bank boosted its stake in Vaxart by 1.1% during the first quarter. Swiss National Bank now owns 250,100 shares of the biotechnology company’s stock worth $1,513,000 after buying an additional 2,600 shares during the last quarter. Kathmere Capital Management LLC boosted its stake in Vaxart by 150.0% during the fourth quarter. Kathmere Capital Management LLC now owns 5,000 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,000 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in Vaxart by 3.2% during the first quarter. UBS Asset Management Americas Inc. now owns 106,102 shares of the biotechnology company’s stock worth $642,000 after buying an additional 3,302 shares during the last quarter. Hedge funds and other institutional investors own 26.42% of the company’s stock.

Vaxart Company Profile (NASDAQ:VXRT)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection.

Recommended Story: What is the Current Ratio?

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.